Large clinical trials can be particularly useful in the early treatment and prevention of neurodegenerative diseases because of the amount of data collected, though patient recruitment and retention are challenging, says biostatistician.
Eli Lilly and Company and AC Immune have signed an agreement for the research and development of tau aggregation inhibitor small molecules, and AC Immune signed a strategic partnership with WuXi biologics.
Previous setbacks in Alzheimer’s disease research for disease-modifying treatments have set the stage for a pipeline of new medicines now moving into clinical trials, according to a recent PhRMA report.
US drug developer Samaritan Pharmaceuticals has filed a patent for
a new drug that could treat a wide range of neurodegenerative
disorders, including Alzheimer's disease, by clearing out amyloid
plaques in the brain.